joined transactions other Thanks, of point had Directors to one with working like wrap wholeheartedly. been third experiences Seymour certainly the of one that accounting think know way past I previous which updated a our old as Audit with up Rich. Yes. Board in with now, issues. that certainly That's LaDuane and that. Not almost months as I I the the is Committee, Chair with background We've great well is a various we in agree for It is as Certainly CFO that news. any had but great quarter. about. way. very the rich strategic Tamara well her line their in And her happy addition was by
upon really what now Turning more KemPharm proposition, really The where expand this about has introduced here. today. value Richard we sit is to
for build in change, platform and will CNS this and company think create think having and which two additional here very focusing outside in we diseases, term. the time opportunities existence. at in as That's a own using on what near leveraging walls hope first to our look technology will to And well really I in our our adapt, approved the be that's least what then are. neurological as we to I partnered this products LAT we
sort aren't FDA LAT level. familiar properties, the mentioned as you're I For sub-optimal that, I the company take concept. poor It's the an or approved fairly the story, going a simple to those the general technology just and some a prodrug of fairly would comes over you technology. high new of with It's couple once spend got absorption, has that molecule product. We minutes that. get a composition entity off. then chemical That directed a his a the same that, have And drug and poor to molecule back We administered it of new of PK, you status. new patents, poor but referred new attached metabolism. matter a from the benefit to ligand, sometimes as as you just
which gives a So of you XXX(b)(X) many product, still cases. you effective the same path have in regulatory the benefits
been. And any has SDX a approved. developed developed was similar containing AZSTARYS we Briefly the kind where – of slide, this approved, been which APADAZ just product of would so was And path. on the basis covering next and and follow we've
a company, Gurnet you the of I've Point. too. which we There's to look been the It's be foundation milestones, as different able the details forward, Point and to future. commercialization want find the the party. this As KPXXX partnered actual AZSTARYS highlighted Capital and on as sure course financial what I'm and already a Corium the with have we business partner do do Gurnet number past, is could portfolio in of in financially we'll which
have triggered after is number window, We then trial Gurnet of SDX a of negotiation right proof-of-concept in XXX-day have first candidates. does right first a our negotiation. Point have we first And flips ROFR. of After man.. to that
ROFR of any First Right and terminates offer terminates third on NDA one-time to an upon acceptance. party So and valid Refusal
if So without hindrance so programs, own impedance to our pursue we GPC. would decide or do from we do
you're and in gives not briefly very spoken for AZSTARYS. I about familiar the you patients this nice the the overview six a of if Many this, and ADHD hope It's price product times product. Turning treatment up. and several of indicated are of you to with
can end, without So or an you without food. take upper restriction this age on the with
concern, You actually people hearing but a the know a we weight And our resonating you of the having a for the open parents especially And changes no IV entire applesauce is than there's here what it we year. and is over children. lot is had capsule and of benefit trial and is a XX% that course on we're or benefit initially duration, assumed, back to sprinkle more this think in lot water. of a a that bit Schedule are of in primary I of of onset was height what there kind little may saw can clinical growing certainly an which to component product, many
they that’s have feedback some captured value that's feedback something think Corium some think that is that patients. I but hear we're certainly And a getting. that could is this so this certainly will physicians initial for believe is value, the I and in lot, And messaging. something their and label have Parents
months efforts continued recent will In it's environment that get and million course. around can commercial across COVID receptivity their paid coming its it I XX think to the and has and over Medicaid sense plan mention the over grow six the it's did launch commercial Corium take so, and will to have that changes to, companies of now make last and launch. they the the lives over physicians, from I've sell nobody made doesn't in that estimate now They at challenging seen The beginning, how of done providers, over something sales momentum when does to of care, patients get to for it's really try general, and this coverage. now course managed lot due think or their the due It launches progress introductions. million. of They'll XX a build Turning course board calls the and payers. briefly months. I and physicians to comes
really are has think many organizations the I payers Corium we think, and I around AZSTARYS. where figured component wins as this with the see ways future out the biggest have, with of
So do. passing we'll updates day-to-day a on exactly the what to we keep tracking best And along of doing basis we're can. as Corium us allows that they're course,
forward excited about why at but before, spend Looking SDX – and of a looking kind second talking this. opportunity I've just here to want highlighted the this I we're about
with profile, Of list based ones product. All course, XX%. the goes that SDX It's refills, prescribers, AZSTARYS This for advantage huge particular that prodrug to Schedule on PK II. based which patients, to product. and and pharmacists, not It's the about in generic for the other day. component Schedule is products. methylphenidate less abusable when the added are throughout also only is perceived there's the for a for we've it's IV trial our can most if to but gradual a that equivalent And be it's sort at a sake, no least Under initiated convenience substituted version states. methylphenidate of safer, And and XXX and a consider We it allows program law And also we in for use on a it's you the continuous for release our unique be indication. recall, disorder. want IND, the exactly with for development. that's the safety where with help The what is future KPXXX effects the looking at at drug stimulant by end recently now SDX. still to inform SDX track pharmacokinetic and year. some It's of though investigate study with where you of the in the release we to this high head want of on exploratory happens is goal data us doses,
well we've which in as idiopathic methylphenidate has stimulant mentioned a SUD past. sleep been use is or investigated which used disorder, disorder, also I've severe hypersomnia as others, for the So
succeed what development how be i.e., hand, in clinical clinical make how to and data this that with and going so do different And decisions going business risk. clinical is likely to based a to our risk, number here we're on of we're factors, will
So under not is risk the what development challenges may we appreciated. see be path. something during Regulatory to actually
you're difficult approval. that the that opportunity, of road. else will Commercial there a anything I've that difficult and of And just are products of if gets take big it's when it's We the end faster. always FDA product. it sense We the make to right. everyone, even Cost just challenge task as as to and much convince things might know, going is because we're already longer we far this that approval, the part, a all, the to the right an cases. to doing. investors approved the have it many have time though needed, like other go what out cheaper already It's time hard be in as informed the First right? to more equal, time SUD have in a come development, a you'd makes sure on is choice, all value well as right and space with It that more always
of of want all these run our with So don't up considerations own We ROFNs. other as butt We to don't step with to those generally will against the well right? to products. We toes strategy, be want ROFRs on that don't – as AZSTARYS. and difficulties into want part
will those of decision. be of All our components
actually LaDuane update. this be turning call over time, to with provides at a I'll you Dwayne the So financial LaDuane? who
